Introduction: Lung tuberculosis, resulting from decreased cellular immunity, is associated with malignancies and is most frequently seen in Hodgkin's disease, leukemia and T-cell lymphoma.
Material And Methods: In the period 1995-2000, 20 patients (pts) with lung tuberculosis and hematological malignancies were analyzed, out of whom 7 (35%) were females, with mean age of 56 years, and 13 (65%) were males, with mean age of 55 years.
Results And Discussion: Among the affected, 8 (40%) patients had Non-Hodgkin's lymphoma, 5 (25%) suffered from chronic lymphocytic leukemia, 4 (2%) had Hodgkin's disease, 1 (5%) manifested a myelodysplastic syndrome, 1 (5%) multiple myeloma and 1 (5%) had chronic myeloid leukemia. The average time from completing a specific cancer therapy and development of tuberculous infection was 20 months, except in 3 cases who had a hematological malignancy and lung tuberculosis at the time of initial diagnosis. The diagnosis was made on the basis of positive findings of sputum smear in 15 (75%) pts, by bronchological examination and sputum analysis in 3 (15%) pts, lymph node biopsy and sputum analysis in 1 (5%) case, pleural biopsy in 1 (5%) patient, and finally confirmed by culture in 19 (95%) pts. Radiological examination revealed fibrocaseous tuberculosis in 14 (70%) pts, out of whom 12 with bilateral and 2 with unilateral changes, 3 (15%) manifested miliary tuberculosis, and 3 (15%) had pleural effusion and tuberculosis.
Conclusion: Successful outcome was achieved in 18 (90%) pts, while lethal outcome was reported in 2 (10%) cases with miliary pulmonary tuberculosis.
Download full-text PDF |
Source |
---|
Antimicrob Agents Chemother
January 2025
Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, Texas, USA.
The impact of heteroresistance on tuberculosis (TB) treatment outcomes is unclear, as is the role of different rifampin and isoniazid exposures on developing resistance mutations. Hollow fiber system model of TB (HFS-TB) units were inoculated with drug-susceptible () and treated with isoniazid and rifampin exposure identified in a clinical trial as leading to treatment failure and acquired drug resistance. Systems were sampled for drug concentration measurements, estimation of total and drug-resistant , and small molecule overlapping reads (SMOR) analysis for the detection of heteroresistance.
View Article and Find Full Text PDFOpen Forum Infect Dis
January 2025
Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Background: The global resurgence of disseminated tuberculosis (TB) after the coronavirus disease 2019 pandemic highlights the necessity of understanding host risk factors, especially in adults without human immunodeficiency virus.
Methods: We reviewed TB cases admitted to Shanghai Public Health Clinical Center from 2017 to 2022. We analyzed baseline characteristics and outcomes.
F1000Res
January 2025
Faculty of Medicine and Health Sciences, Division of Epidemiology and Biostatistics, Stellenbosch University Centre for Evidence-Based Health Care, Cape Town, South Africa.
Background: Tuberculosis (TB) is a leading cause of death worldwide with over 90% of reported cases occurring in low- and middle-income countries (LMICs). Pre-treatment loss to follow-up (PTLFU) is a key contributor to TB mortality and infection transmission.
Objectives: We performed a scoping review to map available evidence on interventions to reduce PTLFU in adults with pulmonary TB, identify gaps in existing knowledge, and develop a conceptual framework to guide intervention implementation.
Introduction Tuberculosis (TB) is an infectious disease caused by . Various studies have established an association between diabetes mellitus (DM) and pulmonary TB. This study describes the prevalence of DM and its predictors in smear-positive TB patients.
View Article and Find Full Text PDFLiver injury in tuberculosis patients, associated with noncompliance with treatment, is further exacerbated by viral hepatitis, which not only directly harms the liver but also increases susceptibility to drug-induced liver injury. The aim of this study was to analyze the associated risk factors for viral hepatitis in tuberculosis patients. This systematic review and meta-analysis adhere to the PRISMA 2020 statement, and the protocol has been registered with PROSPERO (CRD42023477241).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!